
Lucid Diagnostics (LUCD) Stock Forecast & Price Target
Lucid Diagnostics (LUCD) Analyst Ratings
Bulls say
Lucid Diagnostics Inc. is experiencing positive momentum in its growth, with EsoGuard test volumes increasing by 2% year-over-year to 2,841 tests in 3Q25, surpassing initial estimates. The company is expected to achieve rapid revenue growth as it expands coverage through Medicare and various insurance plans, enhancing accessibility to its critically important diagnostic tools. Additionally, a favorable MolDX CAC meeting indicates potential for positive Medicare coverage decisions, which could significantly enhance the company's market reach and financial performance, presenting considerable upside potential.
Bears say
Lucid Diagnostics reported a pro forma net loss of $9.9 million for Q3 2025, slightly exceeding both internal estimates and consensus projections, which highlights ongoing financial challenges. Additionally, the decline in EsoGuard test processing, down to 2,756 tests in Q2 from previous quarters, raises concerns over the slowing adoption of their flagship product amidst competitive pressures and potential reimbursement issues. Coupled with significant risks related to product efficacy, regulatory approvals, and broader liquidity concerns, the company faces a precarious outlook that may hinder future growth and profitability.
This aggregate rating is based on analysts' research of Lucid Diagnostics and is not a guaranteed prediction by Public.com or investment advice.
Lucid Diagnostics (LUCD) Analyst Forecast & Price Prediction
Start investing in Lucid Diagnostics (LUCD)
Order type
Buy in
Order amount
Est. shares
0 shares